{
    "2020-05-02": [
        [
            {
                "time": "",
                "original_text": "COVID-19研发动态：Vir/Alnylam确定候选RNA疗法；和铂医药，君实生物中和抗体开发获得进展",
                "features": {
                    "keywords": [
                        "COVID-19",
                        "RNA疗法",
                        "和铂医药",
                        "君实生物",
                        "中和抗体"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}